Search

everythinglearnresearchcommunity

for

Search:↓

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.

A user is seeking a titanium dioxide-free finasteride pill due to health concerns. They have not found a suitable supplier yet.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.

The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.

The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.

Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.

Koshine KX-826 has different versions, and the green version uses a plant-based carrier that may be less irritating for those sensitive to propylene glycol. Users report irritation with some versions of KX-826.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

RU58841 powder storage, with differing opinions on whether to store it in the freezer or at room temperature. One user prefers the freezer, while a company suggests room temperature.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Verteporfin considered for treating donor areas after hair transplants.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

RU58841 solution developed crystals after refrigeration. Letting it reach room temperature and shaking can dissolve the crystals.

The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.

The conversation is about where to buy RU58841 without propylene glycol. The user also asks if anyone else has tried RU58841.

The conversation discusses whether finasteride would still be necessary if Verteporfin becomes a successful hair loss treatment. It also explores the sensitivity of transplanted hair to DHT and the potential for off-label use of Verteporfin post hair transplant.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.

The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.